LXEO Logo

Lexeo Therapeutics, Inc. (LXEO) Stock Forecast & Price Prediction

Live LXEO Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$4.95

-0.47 (-8.67%)

12 Month Price Forecast For LXEO

$4.95
Current Price
$179.28M
Market Cap
7 Ratings
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to LXEO Price Forecasts

+465.7%
To High Target of $28.00
+364.6%
To Median Target of $23.00
+223.2%
To Low Target of $16.00

LXEO Price Momentum

-8.8%
1 Week Change
-27.4%
1 Month Change
-70.6%
1 Year Change
-24.8%
Year-to-Date Change
-74.6%
From 52W High of $19.50
+6.0%
From 52W Low of $4.67

๐Ÿค” Considering Lexeo Therapeutics (LXEO)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 8, 2025 4:06 AM UTC

LXEO Analyst Ratings & Price Targets

Based on our analysis of 8 Wall Street analysts, LXEO has a consensus that is bullish. The median price target is $23.00, with forecasts ranging from $16.00 to $28.00. Currently, there are 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.

With LXEO currently trading at $4.95, the median price forecast suggests a 364.6% upside. The most optimistic forecast comes from Brian Skorney at Baird, projecting a 465.7% upside, while at provides the most conservative target, suggesting a 223.2% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

LXEO Analyst Consensus

7
Buy
0
Hold
0
Sell

LXEO Price Target Range

Low
$16.00
Average
$23.00
High
$28.00
Current: $4.95

Latest LXEO Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for LXEO.

Date Firm Analyst Rating Change Price Target
Jan 21, 2025 RBC Capital Luca Issi Outperform Reiterates $24.00
Nov 14, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Maintains $23.00
Nov 13, 2024 Chardan Capital Geulah Livshits Buy Maintains $25.00
Nov 13, 2024 Leerink Partners Mani Foroohar Outperform Maintains $19.00
Oct 31, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Reiterates $21.00
Oct 30, 2024 Chardan Capital Geulah Livshits Buy Maintains $23.00
Oct 25, 2024 Chardan Capital Geulah Livshits Buy Maintains $23.00
Aug 14, 2024 Chardan Capital Geulah Livshits Buy Maintains $23.00
Aug 13, 2024 RBC Capital Luca Issi Outperform Reiterates $24.00
Aug 13, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Maintains $21.00
Jul 16, 2024 Chardan Capital Buy Maintains $0.00
Jul 16, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Reiterates $22.00
Jul 15, 2024 Chardan Capital Geulah Livshits Buy Maintains $23.00
Jun 13, 2024 Baird Brian Skorney Outperform Initiates $28.00
Jun 6, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Initiates $22.00
Mar 12, 2024 RBC Capital Luca Issi Outperform Maintains $24.00
Nov 28, 2023 Chardan Capital Geulah Livshits Buy Initiates $23.00
Nov 28, 2023 RBC Capital Luca Issi Outperform Initiates $22.00
Nov 28, 2023 Stifel Paul Matteis Buy Initiates $20.00
Nov 28, 2023 Leerink Partners Mani Foroohar Outperform Initiates $19.00

Stocks Similar to Lexeo Therapeutics, Inc.

The following stocks are similar to Lexeo Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Lexeo Therapeutics, Inc. (LXEO) Financial Data

Lexeo Therapeutics, Inc. has a market capitalization of $179.28M with a P/E ratio of -0.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -74.8%.

Valuation Metrics

Market Cap $179.28M
Enterprise Value $90.11M
P/E Ratio -0.4x
PEG Ratio -2.0x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +106.9%
Current Ratio 9.4x
Debt/Equity 6.6x
ROE -74.8%
ROA -39.9%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. (LXEO) Company Overview

About Lexeo Therapeutics, Inc.

What They Do

Develops gene therapies for genetic diseases.

Business Model

The company operates as a clinical stage genetic medicine firm, focusing on developing gene therapy candidates targeting hereditary and acquired diseases. It generates potential revenue through the successful development and commercialization of its therapies, particularly those aimed at serious conditions such as cardiomyopathies and Batten disease.

Additional Information

Lexeo Therapeutics was incorporated in 2017 and is headquartered in New York, New York. It is currently in the clinical stages of its therapies, which could lead to significant market opportunities if successful in clinical trials and regulatory approvals.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

69

CEO

Mr. R. Nolan Townsend

Country

United States

IPO Year

N/A

Lexeo Therapeutics, Inc. (LXEO) Latest News & Analysis

LXEO stock latest news image
Quick Summary

Lexeo Therapeutics (Nasdaq: LXEO) announced CEO R. Nolan Townsend will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 7, 2025.

Why It Matters

Lexeo Therapeutics' CEO presenting at a major conference may signal potential investor interest, market visibility, and updates on their genetic treatments, impacting stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
LXEO stock latest news image
Quick Summary

Lexeo Therapeutics appointed Dr. Kyle Rasbach as Chief Financial Officer, effective immediately. The company focuses on gene therapies for cardiovascular diseases and Alzheimer's, with key developments expected soon.

Why It Matters

Dr. Rasbach's appointment signals potential strategic shifts and financial stability for Lexeo Therapeutics, which may influence investor confidence amidst upcoming program developments.

Source: GlobeNewsWire
Market Sentiment: Neutral
LXEO stock latest news image
Quick Summary

Lexeo Therapeutics reached FDA alignment on registrational endpoints for LX2006, received RMAT designation, and completed enrollment in key trials. It has $157M in cash, ensuring operational support until 2027.

Why It Matters

FDA alignment on LX2006's development plan and RMAT designation suggest a faster route to market, potentially boosting investor confidence and stock value for Lexeo Therapeutics.

Source: GlobeNewsWire
Market Sentiment: Neutral
LXEO stock latest news image
Quick Summary

Lexeo Therapeutics reported positive interim data for LX1001, the first gene therapy targeting the genetic cause of APOE4-associated Alzheimer's disease.

Why It Matters

Positive interim data for LX1001 could indicate a breakthrough in Alzheimer's treatment, potentially increasing Lexeo Therapeutics' stock value and attracting investor interest in biotech innovations.

Source: GlobeNewsWire
Market Sentiment: Neutral
LXEO stock latest news image
Quick Summary

Lexeo Therapeutics (Nasdaq: LXEO) will present interim data on LX1001, a gene therapy for Alzheimer's, at the CTAD conference from Oct 29-Nov 1, 2024, highlighting safety and biomarker findings.

Why It Matters

The late-breaking presentation of LX1001's interim data at a major conference highlights potential breakthroughs in Alzheimer's treatment, which could significantly impact Lexeo Therapeutics' stock and investor sentiment.

Source: GlobeNewsWire
Market Sentiment: Neutral
LXEO stock latest news image
Quick Summary

Lexeo Therapeutics (Nasdaq: LXEO) will present at upcoming investor conferences, focusing on its work in genetic treatments for cardiovascular diseases and Alzheimer's.

Why It Matters

Lexeo Therapeutics' participation in investor conferences signals active engagement with the investment community, potentially boosting investor interest and stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About LXEO Stock

What is Lexeo Therapeutics, Inc.'s (LXEO) stock forecast for 2025?

Based on our analysis of 8 Wall Street analysts, Lexeo Therapeutics, Inc. (LXEO) has a median price target of $23.00. The highest price target is $28.00 and the lowest is $16.00.

Is LXEO stock a good investment in 2025?

According to current analyst ratings, LXEO has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.95. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for LXEO stock?

Wall Street analysts predict LXEO stock could reach $23.00 in the next 12 months. This represents a 364.6% increase from the current price of $4.95. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Lexeo Therapeutics, Inc.'s business model?

The company operates as a clinical stage genetic medicine firm, focusing on developing gene therapy candidates targeting hereditary and acquired diseases. It generates potential revenue through the successful development and commercialization of its therapies, particularly those aimed at serious conditions such as cardiomyopathies and Batten disease.

What is the highest forecasted price for LXEO Lexeo Therapeutics, Inc.?

The highest price target for LXEO is $28.00 from Brian Skorney at Baird, which represents a 465.7% increase from the current price of $4.95.

What is the lowest forecasted price for LXEO Lexeo Therapeutics, Inc.?

The lowest price target for LXEO is $16.00 from at , which represents a 223.2% increase from the current price of $4.95.

What is the overall LXEO consensus from analysts for Lexeo Therapeutics, Inc.?

The overall analyst consensus for LXEO is bullish. Out of 8 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $23.00.

How accurate are LXEO stock price projections?

Stock price projections, including those for Lexeo Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.